Intractable Seizures & Medical Marijuana: Pennsylvania & West Virginia Qualifying Condition Guide

Intractable seizures also called drug-resistant or refractory epilepsy can occur when seizures continue despite adequate trials of two or more appropriately chosen and dosed antiseizure medications. This affects an estimated 30% of people with epilepsy. Pennsylvania and West Virginia both recognize intractable seizures as a qualifying condition for medical marijuana. If you or a loved one continues to have seizures despite treatment, Compassionate Certification Centers can help you understand your options and determine whether certification may be appropriate as part of your neurological care.

Intractable seizures are one of the few areas in this field with genuine FDA-approved pharmaceutical precedent, but the evidence is more specific and more nuanced than it is often portrayed. A purified CBD medication is FDA-approved for three specific, severe epilepsy syndromes; it is not approved for intractable seizures broadly, and it is not the same as cannabis or CBD products sold outside a pharmacy. At the same time, products containing THC can trigger or worsen seizures in some patients. This page presents that full picture clearly, because the distinction matters significantly for patient safety.

BOOK NOW

• Detailed medical history and description of seizure onset, duration, and pattern
• Electroencephalogram (EEG) to record electrical brain activity
• MRI or CT imaging to identify structural causes
• Genetic testing, particularly in pediatric or treatment-resistant cases
• Confirmation that seizures continue despite adequate trials of two or more appropriately dosed antiseizure medications

BOOK NOW

• Anxiety or unusual sensations before a seizure
• Confusion during or after a seizure
• Convulsions or jerking movements
• Falling
• Loss of bowel or bladder control
• Loss of consciousness
• Muscle rigidity
• Tremors or twitching
• Tongue biting
• Staring into space (absence seizures)
• Weakness or fatigue following a seizure

BOOK NOW

This is the condition with the clearest FDA precedent for a cannabis-derived medication anywhere in this field — but it’s important to understand precisely what is and is not approved, and for whom. The evidence strongly distinguishes between purified, pharmaceutical-grade CBD and broader cannabis or THC-containing products, which carry a documented risk of worsening seizures in some patients. This section presents that full picture. It is informational only and does not constitute medical advice.

1. Epidiolex (CBD): FDA-Approved for Three Specific Syndromes — Not “Intractable Seizures” Broadly

In June 2018, the FDA approved Epidiolex, a plant-derived, pharmaceutical-grade CBD oral solution, for seizures associated with Lennox-Gastaut syndrome and Dravet syndrome in patients 2 years and older — the first FDA approval of any marijuana-derived medication. The approval was based on randomized, double-blind, placebo-controlled trials finding meaningful reductions in seizure frequency compared to placebo. Epidiolex was later also approved for seizures associated with tuberous sclerosis complex in patients 1 year and older. This approval is specific to this pharmaceutical formulation of CBD for these three syndromes, based on the controlled trials that supported it. It is not an approval of “intractable seizures” as a general category, and the FDA has been explicit that it is not an approval of marijuana broadly or of any other cannabis-derived product.

2. Evidence Outside the Three Approved Syndromes: More Limited Than Often Portrayed

Many people with intractable seizures have epilepsy syndromes other than Lennox-Gastaut syndrome, Dravet syndrome, or tuberous sclerosis complex. Evidence for CBD’s effectiveness in these other syndromes is considerably more limited, and clinical epilepsy resources explicitly caution that there is no current evidence that CBD or broader medical marijuana use benefits patients whose epilepsy is already well-controlled with standard medication. Patients whose intractable seizures fall outside the three FDA-approved syndromes should not assume the Epidiolex trial results apply directly to their situation.

3. A Critical Safety Point: THC Can Trigger or Worsen Seizures

This is a point that is often overlooked in marketing materials aimed at patients with treatment-resistant seizures. While purified CBD has anticonvulsant properties in specific syndromes, THC — the primary psychoactive component of cannabis — can have the opposite effect in some circumstances. THC may alter neuronal excitability and has been associated with new-onset seizures, breakthrough seizures in patients with previously controlled epilepsy, and worsened seizure control, particularly with high-potency or synthetic cannabinoid products. A 2022 scoping review found that 10 of 11 studies examining acute cannabis exposure reported a higher-than-expected incidence of seizures relative to general population rates. Case reports have also documented patients with focal epilepsy experiencing breakthrough seizures temporally associated with cannabis use.

4. Cannabis Should Never Replace Prescribed Antiseizure Medication

Clinical epilepsy guidance is explicit on this point: there is no current evidence that patients using CBD or medical marijuana can safely stop or reduce their prescribed antiseizure medications on their own, and the limited available evidence actually points against doing so without close medical supervision. Marketing claims describing cannabis as enabling a “gradual decrease” in antiepileptic drug dosages are not supported by rigorous clinical evidence, and unsupervised medication changes carry a real risk of breakthrough seizures or status epilepticus. Any cannabis use for intractable seizures should be considered a potential adjunct to, not a replacement for, prescribed antiseizure medication, and should always be discussed with a treating neurologist or epileptologist.

5. Drug Interactions: An Important Practical Consideration

CBD, including Epidiolex, has documented drug-drug interactions with several common antiseizure medications, including clobazam and valproate, which can affect blood levels of these medications and increase the risk of side effects such as liver enzyme elevations. Patients considering any cannabis-based product for intractable seizures should have these interactions reviewed carefully by their prescribing neurologist, with appropriate monitoring.

6. What About Testimonials and Reports of “Complete Remission”?

Some marketing materials cite patient testimonials or describe complete seizure remission with cannabis use. While some patients and families do report dramatic improvement, these are anecdotal reports, not controlled clinical evidence — they can’t rule out other explanations such as coincidental timing, placebo effect, or concurrent changes in other medications. The rigorous, controlled trial evidence supporting cannabinoid use in epilepsy remains limited to Epidiolex in the three FDA-approved syndromes described above.

BOOK NOW

Both Pennsylvania and West Virginia recognize intractable seizures as a qualifying condition. The certification process with CCC is straightforward:

Step 1. Register over the phone or online, next-day appointments are often available.
Step 2. Meet with a certified medical marijuana physician who will review your seizure history, current antiseizure medications, and treatment-resistance to determine whether certification is appropriate.
Step 3. Receive your medical marijuana card and begin purchasing from licensed dispensaries in Pennsylvania or West Virginia.